Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0128-based randomized phase 2 study in recurrent or advanced endometrial cancer
NL-OMON48725Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sapanisertib, serabelisib and paclitaxel in endometrial cancer (EC) and uterine cancer (4 arms), sponsored by Takeda. Primary endpoint: Progression-free survival. Started Apr 2018; status: active, not recruiting.
02
Drugs
sapanisertibserabelisibpaclitaxel
03
Conditions
endometrial cancer (EC)uterine cancer
Beyond the preview
Go deeper on NL-OMON48725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48725.